Product image of Labrycor (Isoprenaline Hydrochloride) supplied by GNH India

Labrycor

Active Ingredient:
Isoprenaline Hydrochloride
Origin:
EU

Labrycor (Isoprenaline Hydrochloride)

Isoprenaline Hydrochloride, the active ingredient in Labrycor, is a beta‑adrenergic agonist presented as an intravenous solution for intravenous use. It stimulates heart rate and contractility and provides bronchodilation, making it useful in cardiac rhythm disorders and acute bronchospasm.

GNH India supplies Labrycor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. This ensures consistent product availability across diverse markets.

Manufacturer / TM Owner

Macure Healthcare Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Isoprenaline Hydrochloride acts on the cardiac and bronchial beta‑adrenergic pathways to restore rhythm and airway patency.

  • Bradycardia: increases heart rate to maintain adequate cardiac output.
  • Heart block: enhances AV nodal conduction to improve rhythm.
  • Asystole: provides temporary cardiac stimulation until definitive therapy.
  • Asthma: relaxes bronchial smooth muscle to relieve bronchospasm.
  • Bronchospasm: induces bronchodilation for rapid airway opening.

How It Works

  • Isoprenaline Hydrochloride is a non‑selective agonist of β1 and β2 adrenergic receptors. Binding to β1 receptors on cardiac myocytes raises intracellular cyclic AMP, enhancing calcium influx and increasing heart rate and contractile force. Activation of β2 receptors on bronchial smooth muscle similarly raises cAMP, leading to relaxation of airway smooth muscle and bronchodilation. The combined cardiac and pulmonary effects support its use in emergency cardiac and respiratory situations.

Side Effects

Isoprenaline Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Tachycardia: rapid increase in heart rate.
  • Palpitations: sensation of irregular heartbeat.
  • Headache: mild to moderate intensity.
  • Tremor: fine muscle shaking.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: transient skin redness.

Serious or Rare Side Effects

  • Arrhythmias: potentially life‑threatening rhythm disturbances.
  • Myocardial ischemia: reduced blood flow to heart muscle.
  • Severe hypotension: marked drop in blood pressure.
  • Pulmonary edema: fluid accumulation in lungs.

Precautions & Warnings

When using Isoprenaline Hydrochloride, several precautions should be observed to ensure patient safety.

  • Cardiac monitoring: continuous ECG and blood pressure assessment is required.
  • Dose titration: adjust infusion rate based on clinical response and hemodynamics.
  • Contraindications: avoid in patients with severe coronary artery disease or uncontrolled hypertension.
  • Drug interactions: review concomitant medications that affect adrenergic tone.
  • Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Isoprenaline Hydrochloride can interact with other agents, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Beta‑blockers: antagonize therapeutic effects, may precipitate severe bradycardia.
  • Calcium channel blockers (non‑dihydropyridine): increase risk of conduction abnormalities.
  • MAO inhibitors: potentiate hypertensive responses.

Moderate Interactions (Monitor Closely)

  • Diuretics: may exacerbate electrolyte imbalances, affecting cardiac response.
  • Anticholinergic drugs: can modify heart rate response.
  • Tricyclic antidepressants: may enhance arrhythmic risk.

Frequently Asked Questions

Labrycor contains Isoprenaline Hydrochloride, which is employed in emergency settings to treat severe bradycardia, heart block, asystole, and acute bronchospasm such as asthma attacks. It works by stimulating heart activity and relaxing airway smooth muscle.

Isoprenaline Hydrochloride is a non‑selective β1/β2 adrenergic receptor agonist. Activation of β1 receptors in the heart raises cyclic AMP, increasing heart rate and contractility, while β2 activation in the lungs raises cyclic AMP to relax bronchial smooth muscle, producing bronchodilation.

The dosage of Labrycor is individualized. A qualified prescriber determines the infusion rate and total amount based on the patient’s clinical condition, response, and monitoring parameters. No fixed regimen is provided in public product information.

Safety data for Isoprenaline Hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Labrycor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with agents such as dopamine or epinephrine, Isoprenaline provides a stronger β2‑mediated bronchodilatory effect while still offering β1‑driven cardiac stimulation. Its non‑selective profile can be advantageous in combined cardiac‑respiratory emergencies, though the choice depends on the specific clinical scenario.

Labrycor must be stored at 2‑8 °C, protected from light, and kept in its original container. It should not be frozen or shaken. During handling, maintain aseptic technique and avoid temperature excursions that could compromise product stability.

Labrycor is supplied as an injectable solution for intravenous use. It is administered by slow infusion under continuous cardiac and hemodynamic monitoring, with the rate adjusted according to the patient’s response and clinical objectives.

Serious adverse events include life‑threatening arrhythmias, myocardial ischemia, severe hypotension, and pulmonary edema. Continuous ECG and blood pressure monitoring are essential to detect these complications early and intervene promptly.

Labrycor is contraindicated in patients with severe coronary artery disease, uncontrolled hypertension, or known hypersensitivity to isoprenaline. Caution is also advised for individuals with existing arrhythmias, significant electrolyte disturbances, or those receiving interacting medications such as beta‑blockers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Isoprenaline Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT